A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Bristol-Myers Squibb
Alterome Therapeutics, Inc.
Verastem, Inc.
Revolution Medicines, Inc.
Erasca, Inc.
Eli Lilly and Company
Revolution Medicines, Inc.
PAQ Therapeutics, Inc.
Mirati Therapeutics Inc.
Eli Lilly and Company
Fate Therapeutics
Eastern Cooperative Oncology Group
Fate Therapeutics
NKGen Biotech, Inc.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Institut du Cancer de Montpellier - Val d'Aurelle
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Medical University of South Carolina
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
University of Massachusetts, Worcester
University of Miami
Royal Marsden NHS Foundation Trust
New Mexico Cancer Research Alliance
R-Pharm
SWOG Cancer Research Network
Odense University Hospital
Philipps University Marburg
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Alabama at Birmingham
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Eli Lilly and Company
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente